Evidence map›Paper›PMID 22848439›Full record

ArticlePloS one2012

Mapping MKP-3/FOXO1 interaction and evaluating the effect on gluconeogenesis.

Ping Jiao, Bin Feng, Haiyan Xu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. MAP kinase phosphatases in metabolic diseases.Trends in endocrinology and metabolism: TEM · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Dual-specificity MAP kinase phosphatases in health and disease.Biochimica et biophysica acta. Molecular cell research · 2019
    Review
  7. Mitogen-Activated Protein Kinase Regulation in Hepatic Metabolism.Trends in endocrinology and metabolism: TEM · 2017
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ping JiaoHallett Center for Diabetes and Endocrinology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Bin Feng
Haiyan Xu
Rhode Island Hospital · US

Funding

MAP Kinase Phosphatase 3 (MKP-3) and Obesity-related GluconeogenesisR01DK080746 · NIDDK · RHODE ISLAND HOSPITAL · PI XU, HAIYAN · 2009 to 2013
$1.7M
NIDDK NIH HHS R01 DK080746
6 · The paper itself

Abstract

backgroundMAP kinase phosphatase 3 (MKP-3) is known to attenuate the ERK signaling pathway. It has been recently demonstrated that MKP-3 is also a player in promoting hepatic glucose output in obese state by interacting and activating FOXO1. Reduction of hepatic MKP-3 expression is sufficient to reduce blood glucose levels in both diet-induced and genetically obese mice. METHODOLOGY/PRINCIPAL

findingsIn current study, the mechanism of MKP-3/FOXO1 interaction and the effects on transcription of gluconeogenic gene and glucose output was investigated in Fao hepatoma cells by using mutated MKP-3 and FOXO1 adenoviral constructs. The results indicate that MKP-3 phosphatase activity is not required for MKP-3/FOXO1 interaction but is essential for FOXO1 nuclear translocation and MKP-3 promoted gluconeogenesis. Compared to GFP control (1±0.38), MKP-3 increased G6Pase gene expression by 242% (3.42±0.62) while inactive MKP-3 does not change G6Pase expression (0.98±0.17). The residues 200-260 of MKP-3 and the residues 360-456 of FOXO1 are essential for mediating MKP-3/FOXO1 interaction. Interestingly, ERK phosphorylation deficient but not Akt phosphorylation deficient FOXO1 mutant lost interaction with MKP-3. Furthermore, in vivo experiments showed that Akt phosphorylation resistant FOXO1 3A mutant is sufficient to rescue the hypoglycemia caused by MKP-3 knock down in the liver of lean mice (from 141±6.78 to 209±14.64 mg/dL). CONCLUSIONS/SIGNIFICANCE: 1) Critical residues mediating MKP-3/FOXO1 interaction have been identified; 2) ERK phosphorylation deficient FOXO1 mutant is as potent as Akt phosphorylation deficient FOXO1 mutant in activating transcription of gluconeogenic genes; 3) Constitutively active FOXO1 can rescue the hypoglycemic effect caused by reduced hepatic MKP-3 expression in vivo.

Indexed as

Active Transport, Cell NucleusAnimalsCell LineCell NucleusDual Specificity Phosphatase 6Extracellular Signal-Regulated MAP KinasesForkhead Box Protein O1Forkhead Transcription FactorsGene Expression Regulation, EnzymologicGene Knockdown TechniquesGluconeogenesisGlucose-6-PhosphataseHumansLiverMiceMutationDual Specificity Phosphatase 6Dusp6 protein, mouseExtracellular Signal-Regulated MAP KinasesForkhead Box Protein O1Forkhead Transcription FactorsFoxo1 protein, mouseGlucose-6-PhosphataseProto-Oncogene Proteins c-akt

Identifiers

PMID22848439
PMCPMC3405053
OpenAlexW2012567446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.